Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

Edge bugs are so fetch, and Cisco just dropped 50 new ones, including some heavy hitters with 10 out of 10 scores on the CVSS scale.

With the expansion of ThreatLocker’s deny-by-default approach to the cloud and mobile announced Thursday, the cybersecurity vendor is addressing one of the biggest challenges faced by MSPs today, CEO ...

Microsoft has launched High Volume Email for Exchange Online in public preview, with free access until May 2026 for organizations sending high-volume email.

The browser is becoming the operating system for modern work, yet many enterprises still treat it as an extension of network or endpoint security. Keep Aware's 2026 State of Browser Security Report ...

It's been 30 years since a new drug to delay kidney disease progression in adults with type 1 diabetes was successful in a clinical trial -- the last being the ACE inhibitor captopril in 1993 -- noted ...

Amylyx (AMLX) downgraded to Buy after AMX0035 PSP halt; focus shifts to avexitide Phase 3 with Q3 2026 data and strong cash ...

The findings suggest clinicians don’t need to be as aggressive in lowering BP in this population, at least early after ...

New Jira integrations connect security alerts, access requests and approvals into a single, governed workflow while ...

Can-Fite BioPharma (CANF) stock jumped 107% after namodenoson successfully completed Phase 2a safety testing in 20 pancreatic cancer patients.

Topline results from the MUSCLE study indicate that ulviprubart did not meet its primary endpoint of mean change in inclusion body myositis functional rating scale scores.